Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

STRYKER CORPORATION

(SYK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

STRYKER CORP : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

01/14/2022 | 12:13pm EST

ITEM 7.01 REGULATION FD DISCLOSURE

Effective December 31, 2021, Stryker Corporation (the "Company") will segregate its operations into two reportable business segments: (i) MedSurg and Neurotechnology and (ii) Orthopaedics and Spine. This change realigns the Company's reportable business segments to its new internal reporting structure and how the Company manages its businesses as a result of the previously announced transition of responsibilities of President and Chief Operating Officer, Timothy J. Scannell, and the division of responsibilities between Group Presidents, J. Andrew Pierce (Group President, MedSurg and Neurotechnology) and Spencer S. Stiles (Group President, Orthopaedics and Spine).

For informational purposes, included in Exhibit 99.1 to this report is the Company's recast historical product sales information that reflects the segment change noted above.

The information furnished in this report, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS


  (d) Exhibits

        99.1     Supplemental Product Sales Information
                 Cover Page Interactive Data File (the cover page XBRL tags are embedded
      104        within the Inline XBRL document)

© Edgar Online, source Glimpses

All news about STRYKER CORPORATION
01/20Stryker Announces New Tornier Perform® Patient-Matched Primary Reversed Glenoid
CI
01/14Stryker Restructures Operations Into Two Business Segments
DJ
01/14STRYKER : Supplemental Product Sales Information - Form 8-K
PU
01/14STRYKER CORP : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
01/11STRYKER CORP : Entry into a Material Definitive Agreement, Financial Statements and Exhibi..
AQ
01/10NORTH AMERICAN MORNING BRIEFING : Yields Rise, -3-
DJ
01/07Stryker's Offer for Vocera Looks 'Rich' But Deal Rationale 'Justified,' RBC Says
MT
01/07Stryker's $3 Billion Vocera Deal Represents 'Rich' Valuation, But Strategic Rationale J..
MT
01/07Today on Wall Street: Is it legit?
01/07Morgan Stanley Downgrades Stryker to Equalweight From Overweight; Price Target is $305
MT
More news
Analyst Recommendations on STRYKER CORPORATION
More recommendations
Financials (USD)
Sales 2021 17 057 M - -
Net income 2021 2 146 M - -
Net Debt 2021 9 265 M - -
P/E ratio 2021 44,0x
Yield 2021 0,99%
Capitalization 96 075 M 96 075 M -
EV / Sales 2021 6,18x
EV / Sales 2022 5,65x
Nbr of Employees 43 000
Free-Float -
Chart STRYKER CORPORATION
Duration : Period :
Stryker Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends STRYKER CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Last Close Price 254,68 $
Average target price 286,59 $
Spread / Average Target 12,5%
EPS Revisions
Managers and Directors
Kevin A. Lobo Chairman, President & Chief Executive Officer
Timothy J. Scannell Executive Advisor
Glenn S. Boehnlein Chief Financial Officer & Vice President
Alan Douville Chief Information Officer & Vice President
Dana S. McMahon Chief Compliance Officer & Vice President
Sector and Competitors